Use of pasteurized Akkermansia for treating metabolic disorders

Abstract

The present invention relates to pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of pasteurized Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

The invention claimed is: 
     
       1. A method for treating a metabolic disorder in a human subject in need thereof comprising orally administering a therapeutically effective amount of pasteurized  Akkermansia muciniphila  or fragments thereof to the subject, wherein the  Akkermansia muciniphila  has been pasteurized at a temperature in a range of from 50° C. to 100° C. prior to administration, thereby treating the metabolic disorder in the subject. 
     
     
       2. The method according to  claim 1 , wherein said metabolic disorder is obesity. 
     
     
       3. The method according to  claim 1 , wherein said metabolic disorder is selected from the group consisting of metabolic syndrome; insulin-deficiency or insulin-resistance related disorders; Diabetes Mellitus including Type 2 Diabetes; glucose intolerance; abnormal lipid metabolism; atherosclerosis; hypertension; pre-eclampsia; cardiac pathology; stroke; non-alcoholic fatty liver disease; hyperglycemia; hepatic steatosis; liver diseases including fibrosis associated with obesity and abnormal liver functions, selected from changes in bile production and immunity; dyslipidemia; dysfunction of the immune system associated with overweight and obesity; inflammatory, immune and barrier function diseases selected from inflammatory bowel disease, Crohn's disease, ulcerative colitis, and irritable bowel syndrome; cardiovascular diseases; high cholesterol; elevated triglycerides; asthma; sleep apnea; osteoarthritis; neuro-degeneration; gallbladder disease; syndrome X; atherogenic dyslipidemia and cancer. 
     
     
       4. The method according to  claim 1 , wherein the therapeutically effective amount is an amount of  Akkermansia muciniphila  ranging from about 1.10 4  to about 1.10 12  cells. 
     
     
       5. The method according to  claim 1 , wherein the therapeutically effective amount of  Akkermansia muciniphila  is administered at least three times a week. 
     
     
       6. The method according to  claim 1 , wherein the therapeutically effective amount of  Akkermansia muciniphila  is co-administered with another probiotic strain and/or another bacteria and/or microorganisms with beneficial effects and/or with one or more prebiotics. 
     
     
       7. The method according to  claim 1 , wherein the therapeutically effective amount of  Akkermansia muciniphila  or fragment thereof is contained in a composition in association with an excipient. 
     
     
       8. The method according to  claim 1 , wherein the therapeutically effective amount of  Akkermansia muciniphila  or fragment thereof is contained in a nutritional composition. 
     
     
       9. The method according to  claim 1 , wherein the therapeutically effective amount of  Akkermansia muciniphila  or fragment thereof is contained in a pharmaceutical composition in association with a pharmaceutically acceptable vehicle. 
     
     
       10. A method for promoting weight loss in a human subject in need thereof comprising orally administering a therapeutically effective amount of pasteurized  Akkermansia muciniphila  or fragments thereof to the subject, wherein the  Akkermansia muciniphila  has been pasteurized at a temperature in a range of from 50° C. to 100° C. prior to administration, thereby promoting weight loss in the subject. 
     
     
       11. The method according to  claim 10 , wherein the method increases energy expenditure of the subject. 
     
     
       12. The method according to  claim 10 , wherein said method does not impact the food intake of said subject. 
     
     
       13. The method according to  claim 10 , wherein the therapeutically effective amount is an amount of  Akkermansia muciniphila  ranging from about 1.10 4  to about 1.10 12  cells. 
     
     
       14. The method according to  claim 10 , wherein the method increases satiety in the subject.